Formulation development of a recombinant VAR2-antiCD3 protein for cancer immunotherapy
The use of immunotherapy for treating cancer has received a lot of attention in the recent years. The therapy is based on activating or deactivating the patient’s own immune system to help fight the disease. One way of doing this, is using bispecific molecules that can target both cancer cells and T-cells simultaneously. In 2003, a researcher found that the surface protein VAR2, expressed on mala
